Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Cardiac MRI strengthens suspicion for cardiac amyloid by characterizing tissue, but its findings are supportive, not definitive.
- It doesn’t establish the ATTR subtype alone and doesn’t replace monoclonal testing or bone-avid scintigraphy.
- MRI changes interpretation most when the rest of the workup is equivocal or bone-avid scintigraphy is uncertain or contraindicated.
- Protocol, scanner, rhythm, renal, and device factors shape interpretation, so MRI is read within the broader amyloidosis workup.
Where Cardiac MRI Adds the Most Value
Cardiac MRI is particularly useful when the clinical presentation, biomarkers, or echocardiographic findings raise suspicion for ATTR-CM, but additional tissue characterization is required to support the diagnosis. Characteristic late gadolinium enhancement, abnormal myocardial nulling, and expanded extracellular space can support the diagnosis of cardiac amyloidosis and help define disease burden. It complements echocardiography and bone-avid scintigraphy within the diagnostic workup but doesn’t replace any component of it.
Why MRI Findings Stay Supportive, Not Definitive
MRI findings are supportive but not diagnostic of ATTR-CM. Cardiac MRI doesn’t establish the ATTR subtype on its own nor does it replace monoclonal protein testing, bone-avid scintigraphy, or tissue typing when subtype determination changes management. These findings assist in the differential diagnosis without finalizing it.
When MRI Most Changes Interpretation
Cardiac MRI changes interpretation most when the rest of the workup is equivocal—for example, when bone-avid scintigraphy is uncertain or contraindicated, or when a clinician needs to separate an infiltrative process from non-infiltrative hypertrophy before proceeding with confirmatory diagnostic testing. Even there, characteristic cardiac MRI findings are suggestive of cardiac amyloidosis but should be followed by appropriate confirmatory investigations, including 99mTc-PYP scintigraphy and monoclonal protein studies.
Interpreting Cardiac MRI Within the Diagnostic Workup Cardiac MRI findings should always be interpreted within the appropriate clinical context. Protocol quality, scanner differences, rhythm issues, renal limitations, implanted devices, and local expertise all affect acquisition and interpretation. Cardiac MRI findings should therefore be interpreted within the broader amyloidosis workup rather than as independent evidence to confirm or exclude the diagnosis. When the diagnosis has been established, attention shifts to the ATTR-CM treatment landscape.
Clinical Decision Point
Cardiac MRI is a triage and tissue-characterization tool, not the step that assigns subtype. Use it to strengthen or weaken suspicion and to decide who needs confirmatory monoclonal testing and bone-avid imaging or biopsy with typing. Clinical decision-making should be based on how the tissue findings fit the phenotype and the rest of the workup, not on the scan alone.
Frequently Asked Questions
What is the primary role of cardiac MRI in the evaluation of suspected ATTR-CM?
Cardiac MRI provides tissue-level characterization that can strengthen or weaken suspicion for cardiac amyloidosis when the clinical phenotype is suggestive but not yet confirmed.
Can cardiac MRI establish ATTR-CM subtype on its own?
No. It can strengthen suspicion for cardiac amyloid, but it doesn’t determine the ATTR subtype and doesn’t replace monoclonal testing or scintigraphy.
When does cardiac MRI most change interpretation?
Cardiac MRI is particularly valuable when the diagnostic evaluation is inconclusive, when bone-avid scintigraphy is inconclusive or contraindicated, or when differentiation of infiltrative cardiomyopathy from other causes of left ventricular hypertrophy is required.
What are the main limitations of cardiac MRI interpretation in ATTR-CM?
Limitations include protocol quality, scanner differences, rhythm issues, renal constraints, devices, local expertise, and the need to read the result alongside the rest of the workup.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- A Review of Current and Evolving Imaging Techniques in Cardiac Amyloidosis. Current Treatment Options Cardiovascular Medicine
- Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy. JACC Cardiovascular Imaging
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.